SKLB083017

N/A

Report date: 2024/09/10 11:03:07

Base Information

Drug NameSKLB083017
Drug Alias NameSKLB083017SKLB-083017
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonists
TargetsVascular endothelial growth factor receptor 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Galaxy Biopharma Co LtdSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Galaxy Biopharma Co LtdSichuan UniversityGalaxy Biomedical Investment Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A